Chemotherapy for germ cell tumors relapsing after high-dose chemotherapy and stem cell support: A retrospective multicenter study of the Austrian Study Group on Urologic Oncology

Annals of Oncology

Volumn 8, Issue 12, 1997, Pages 1229-1234

  Pont, J ^a,b,f   Bokemeyer, C ^c   Harstrick, A ^d   Sellner, F ^e   Greinix, H ^f   Stoiber, F ^a,e  

^a Kaiser Franz Josef Spital   (Austria)

^b 3rd Medical Department Oncology   (Austria)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e Krankhs der Barmherzigen Schwestern ^*  (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cisplatin refractory patients; Germ cell cancer; Ifosfamide; Paclitaxel; Post HDCT chemotherapy

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL;

ADULT; ARTICLE; AUSTRIA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; GERM CELL TUMOR; GERMANY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; SWITZERLAND; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUSTRIA; CISPLATIN; GERMANY; GERMINOMA; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SWITZERLAND; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 0031432918     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008286305312     Document Type: Article

References (21)

1. Einhorn LH. Salvage therapy for germ cell tumors. Semin Oncol 1994; 4: Suppl 7: 47-51.
2. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables. J Clin Oncol 1996; 14: 2638-45.
3. Miller JC, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990; 1 (Suppl 2): 36-9.
4. Motzer RJ, Bajorin DF, Schwartz LH et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277-83.
5. Bokemeyer C, Schmoll HJ, Natt F et al. Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cispiatinrefractory testicular cancer. J Cancer Res Clin Oncol 1994; 120: 754-7.
6. Bokemeyer C, Beyer J, Metzner B et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996; 7: 31-4.
7. Bokemeyer C, Hartmann JT, Kuczyk MA et al. The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumors. World J Urol 1996; 14: 354-9.
8. Siegert W, Beyer J, Strohscher I et al. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: A phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 1994; 12: 1223-31.
9. Linkesch W, Greinix HT, Höcker P et al. Long-term follow up of phase I/II trial of ultrahigh carboplatin, VP 16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. Proc Am Soc Clin Oncol 1993; 12: 232 (Abstr 717).
10. Bokemeyer C, Harstrick A, Ruther U et al. Sequential high-dose VIP-chemotherapy plus peripheral stem cell (PBSC) support for advanced germ cell cancer. Ann Oncol 1996; 7 (Suppl 5): 55 (Abstr 259O).
11. Armitage P, Berry G. Statistical Methods in Medical Research, third ed. Oxford, UK: Blackwell Scientific 1994.
12. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972; 34: 187-220.
13. Motzer RJ. Selecting patients with cisplatin-resistant germ cell tumors for high-dose chemotherapy. J Clin Oncol 1996; 14: 2625-6.
14. Murphy BR, Breeden ES, Donohue JP et al. Surgical salvage of chemorefractory germ cell tumors. J Clin Oncol 1993; 11: 324-9.
15. Greco FA, Johnson DH, Hainsworth JD. Chronic oral etoposide. Cancer 1991; 67: 303-9.
16. Gerl A, Wilmanns W. Antitumor activity of paclitaxel after failure of high-dose chemotherapy in a patient with late relapse of a non-seminomatous germ cell tumor. Anti-Cancer Drugs 1996; 7: 716-8.
17. Williams SD, Einhorn LH, Greco FA et al. VP-16-213 salvage therapy for refractory germinal neoplasms. Cancer 1980; 46: 2154-8.
18. Wheeler BM, Loehrer PJ, Williams SD et al. Ifosfamide in refractory germ cell tumors. J Clin Oncol 1986; 4: 28-34.
19. Motzer RJ, Chou TC, Schwarzt L et al. Paclitaxel in germ cell cancer. Semin Oncol 1995; 3: 12-5.
20. Reed E, Parker RJ, Dabholkar M. Taxol effect on cisplatin-DNA adduct repair in human ovarian cancer cells. Second National Cancer Institute Workshop on Taxol, Alexandria, VA 1992 (Abstr).
21. Droz JP, Culine S, Biron P, Kramar A. High-dose chemotherapy in germ-cell tumors. Ann Oncol 1996; 7: 997-1003.